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AbstrAct
Pancreatic ductal adenocarcinomas (PDACs) are hypovascular, but overexpress 
pro-angiogenic factors and exhibit regions of microvasculature. Using RNA-seq data 
from The Cancer Genome Atlas (TCGA), we previously reported that ~12% of PDACs 
have an angiogenesis gene signature with increased expression of multiple pro-
angiogenic genes. By analyzing the recently expanded TCGA dataset, we now report 
that this signature is present in ~35% of PDACs but that it is mostly distinct from an 
angiogenesis signature present in pancreatic neuroendocrine tumors (PNETs). These 
PDACs exhibit a transcriptome that reflects active TGF-β signaling, and up-regulation 
of several pro-inflammatory genes, and many members of JAK signaling pathways. 
Moreover, expression of SMAD4 and HDAC9 correlates with endothelial cell abundance 
in PDAC tissues. Concomitantly targeting the TGF-β type I receptor (TβRI) kinase with 
SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks 
proliferative cross-talk between human pancreatic cancer cells (PCCs) and human 
endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 
silencing in ECs. By contrast, either inhibitor alone does not suppress their enhanced 
proliferation in 3D co-cultures. These findings suggest that targeting both TGF-β and 
JAK1 signaling could be explored therapeutically in the 35% of PDAC patients whose 
cancers exhibit an angiogenesis gene signature.
IntroductIon
Pancreatic ductal adenocarcinoma (PDAC) is the 
fourth leading cause of cancer-related deaths in the United 
States, with a 5-year survival rate of 7% [1]. Several 
aspects of PDAC pathobiology contribute to this poor 
prognosis. First, approximately 80% of PDAC patients 
are diagnosed at an advanced stage with locally invasive 
and/or metastatic disease which precludes the option of 
life-prolonging tumor resection [2]. Second, PDAC is 
associated with several high frequency driver mutations, a 
plethora of low frequency driver mutations, and excessive 
production of growth factors and their receptors, leading 
to the activation of multiple aberrant signaling pathways 
that promote chemoresistance [3–5]. Third, PDAC 
exhibits intense tumor desmoplasia and a complex 
tumor microenvironment (TME) that is rich in collagens, 
hyaluronan, and fibronectin [6–9], harbors inflammatory 
cells and macrophages, and is generally hypovascular 
and hypoxic [6–9]. Consequently, there is compression 
of the existing vasculature, and attenuated drug delivery 
into the pancreatic tumor mass [6–8, 10]. Fourth, there are 
few gene signatures or biomarkers that will allow for the 
rational design of targeted therapies to specific subgroups 
of PDAC patients. One such example is the use of PARP 
inhibitors in patients with genomic instability and either 
BRCA-1 or -2 mutations, or PALB-2 mutations [4, 11, 12].
Based on analysis of preliminary PDAC 
transcriptome data from The Cancer Genome Atlas 
(TCGA), we previously reported that ~12% of PDACs 
exhibit a pro-angiogenic gene signature [13]. In the 
present study, we analyzed the recently expanded TCGA 
dataset which includes more PDAC cases to understand 
the relationship between this signature and the presence 
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of intratumoral endothelial cells. The expanded dataset 
also includes pancreatic neuroendocrine tumors (PNETs), 
and in contrast to the findings in PDAC, PNETs are often 
highly vascular, yet the prognosis of these patients is better 
than that of patients with PDAC, even in metastatic PNET 
[14]. Although PNETs account for approximately 2% of 
all pancreatic tumors [15], understanding the differences 
between PNETs and PDAC in relation to angiogenesis 
could provide a better understanding for the failure of anti-
angiogenic therapy in PDAC, and could shed new light on 
the reasons for the vastly better prognosis of PNET in spite 
its propensity to metastasize to the liver. 
We now report that a strong angiogenesis gene 
signature is present in ~35% of PDAC cases, and is 
mostly distinct from the angiogenic genes up-regulated 
in PNETs. The same PDAC cases also exhibit a strong 
TGF-β signaling signature. Moreover, in a custom-
prepared tissue microarray (TMA) of PDAC tissues, 
strong SMAD4 immunoreactivity in the cancer cells 
correlates with enhanced microvessel density (MVD). 
PDACs in TCGA, but not PNETs, are also enriched 
in genes implicated in inflammation and JAK/STAT 
signaling. Our previous findings demonstrated that 
ruxolitinib alone suppressed mitogenic effects by murine 
endothelial cells on co-cultured murine pancreatic cancer 
cells (PCCs). By contrast, we now show that concomitant 
inhibition of TGF-β signaling with SB505124 and JAK 
signaling with either ruxolitinib or JAK1-targeting shRNA 
is required to impede human PCC and human endothelial 
cell (EC) mitogenic cross-talk in 3D co-culture of both cell 
types. Therefore, we propose that this combination could 
represent a novel therapeutic approach in PDAC patients 
whose cancers exhibit an angiogenesis gene signature and 
SMAD4-positive cancer cells.
results
PdAcs and Pnets have distinct angiogenesis 
gene signatures
In contrast to the well-vascularized pancreatic 
neuroendocrine tumors (PNETs), pancreatic ductal 
adenocarcinomas (PDACs) are dense and relatively 
hypovascular. Nevertheless, PDACs harbor endothelial 
cells and some exhibit regions rich in microvasculature 
[13]. To assess angiogenic gene expression in PDAC, we 
analyzed pancreatic tumor RNA-Seq data from The Cancer 
Genome Atlas (TCGA). This TCGA dataset was recently 
expanded to 178 patient samples that include PDAC and 
PNET cases. Given the known vascular nature of PNETs, 
their vastly better prognosis by comparison to PDACs, 
the known propensity of both tumor types to metastasize 
to the liver, and the association of tumor angiogenesis 
with the metastatic process, we also examined angiogenic 
gene expression in PNETs. We focused our analysis on 
PNETs (n = 8) and PDACs that lacked secondary or 
unknown histopathological characteristics (n = 135), and 
assessed the expression levels of 129 angiogenesis genes 
that we identified by cluster analysis of PDAC RNA-Seq 
data [13]. Hierarchical clustering revealed that ~35% 
of PDACs (47/135) grouped together and exhibited up-
regulation of multiple angiogenesis genes, whereas ~47% 
(64/135) and ~18% (24/135) had increased expression of 
some or few of these genes (Figure 1A). Thus, there are 
three subgroups of PDAC, each with distinct angiogenesis 
gene expression profiles that we termed as having strong, 
moderate or weak angiogenic gene signatures. By contrast, 
all 8 PNETs grouped together and exhibited increased 
expression of a subset of angiogenesis genes (Figure 1A).
To identify genes up-regulated in PDACs with 
a strong signature and to assess overlap with genes 
up-regulated in PNETs, we next conducted a differential 
expression analysis comparing the strong PDAC 
subgroup or PNETs with the weak subgroup. Out of 129 
angiogenesis genes, 79 were significantly up-regulated 
in PDACs with a strong signature whereas 41 were 
up-regulated in PNETs (Supplementary Table 1). 
Comparison of these gene lists revealed that 31 genes 
were up-regulated in both PDACs and PNETs, including 
FGFR1, and VEGFR-1 (FLT1), −2 (KDR) and −3 (FLT4) 
all of which are pro-angiogenic (Figure 1B, Supplementary 
Table 1). By contrast, 48 genes were significantly 
up-regulated only in PDAC (Figure 1B, Table 1), and 22 
of these genes were directly connected (Supplementary 
Figure 1). Conversely, 10 genes were unique to PNETs, 
and only 2 were functionally connected but in an indirect 
manner (Figure 1B, Table 2, Supplementary Figure 1). 
Thus, many angiogenesis genes are up-regulated in PNETs 
and a subgroup of PDACs, and while the expression of 
some genes overlaps between these tumor types, PDAC 
exhibits increased expression of a larger set of functionally 
connected angiogenesis genes.
PDAC subgroups have similar mutation profiles 
To determine whether the angiogenesis gene 
signature present in 35% of PDACs is associated with a 
specific mutational burden, we gleaned curated mutation 
data from TCGA using version 1.2.0 which included 
information from 98 PDAC and 3 PNET cases. Overall, 
PDACs exhibited more mutations (median = 47) than 
PNETs (median = 19) (Figure 1C), raising the possibility 
that differences in mutational burden could account for 
divergent angiogenic profiles. However, mutations were 
similar across the PDAC subgroups, and consistent with 
PDAC genome sequencing studies [3, 4, 16, 17], KRAS 
(~86%), TP53 (~55%), SMAD4 (19%) and CDKN2A 
(19%) were four of the five most frequently mutated 
genes (Figure 1C). Given that the anticipated mutation 
frequencies of SMAD4 and CDKN2A are 50% and 
90%, respectively [18], these observations suggest that 
TCGA may underestimate the frequency of certain driver 
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mutations. We therefore analyzed copy number data 
to determine whether either of these tumor suppressor 
genes are deleted. SMAD4 and CDKN2A deletions were 
present in ~14% and ~26% of PDACs, respectively 
(Supplementary Figure 2A), indicating that SMAD4 and 
CDKN2A inactivation arises from both mutations and 
homozygous deletions. We next assessed whether any 
genes have different mutational frequencies across the 
Figure 1: PdAcs have varying degrees of an angiogenic gene signature that is distinct from Pnets. (A) Hierarchical 
clustering of RNA-Seq expression values from 129 angiogenic genes in 8 PNET (NET) and 135 PDAC TCGA samples confirms the 
presence of PDAC subgroups with strong, moderate, and weak expression of these genes (red = up-regulated; green = down-regulated). 
(b) Differential expression analysis of the 129 genes between the strong angiogenic PDAC group vs. the weak angiogenic PDAC group 
and the NET group vs. weak angiogenic PDAC group reveals that 31 angiogenic genes are common to both tumor types, whereas 48 and 
10 are unique to strong angiogenic PDACs or PNETs, respectively (Fold Change > = 1.5, False Discovery Rate (FDR) < 0.05). (c) The 
top 34 non-silently mutated genes that appear with a frequency of 6% or more in the 3 NET + 98 PDAC cases combined are listed on the 
left while their mutation frequencies in PDAC are graphed to the right. Samples (left) appear in the same order as the cluster analysis with 
blue indicating a non-silently mutated gene, white a silently mutated or wild type gene, and gray denotes samples that lack mutation data. 
(d) The total number of non-silently mutated genes for NET and PDAC samples was graphed. Median counts are as follows: NET: 19, 
PDAC: 47, Strong Angio PDAC: 40, Moderate Angio PDAC: 48, Weak Angio PDAC: 64.
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table 1: Genes unique to the PdAc angiogenesis gene signature
number Gene symbol Fold change P-value Fdr
1 ACVRL1 1.76 1.04E-04 7.61E-04
2 ANGPT1 3.38 4.31E-08 8.07E-07
3 APOD 2.07 2.25E-03 1.04E-02
4 C3 2.1 1.30E-05 1.24E-04
5 C3AR1 3.23 2.08E-11 1.04E-09
6 C6 2.32 5.79E-03 2.28E-02
7 CCR2 5.7 3.24E-13 2.90E-11
8 CLIC4 2.75 5.92E-12 3.47E-10
9 CMA1 11.66 1.09E-03 5.65E-03
10 COL15A1 3.2 2.23E-15 4.01E-13
11 COL4A3 3.72 1.81E-03 8.67E-03
12 CXCL12 3.48 2.35E-11 1.16E-09
13 CYP1B1 7.4 1.51E-29 1.50E-25
14 ECSCR 1.69 4.01E-03 1.69E-02
15 ELK3 2.62 1.16E-08 2.57E-07
16 ENPEP 2.73 2.38E-08 4.86E-07
17 EPAS1 1.65 2.06E-04 1.37E-03
18 GJA5 1.87 1.07E-04 7.77E-04
19 GNA13 1.73 2.31E-04 1.50E-03
20 GPR124 2.89 1.72E-12 1.21E-10
21 GREM1 3.82 2.90E-04 1.83E-03
22 HAND2 2.28 1.47E-04 1.02E-03
23 HDAC9 1.82 9.78E-03 3.50E-02
24 HIF1A 2.01 2.14E-06 2.54E-05
25 HIPK1 1.63 5.16E-04 3.00E-03
26 ITGAV 2.2 1.10E-07 1.86E-06
27 ITGB1 1.68 3.43E-04 2.11E-03
28 JAM3 1.75 2.41E-04 1.56E-03
29 MAP3K7 1.57 4.48E-03 1.84E-02
30 MEOX2 3.63 2.35E-08 4.81E-07
31 NRP1 2.38 8.17E-10 2.59E-08
32 PIK3CA 2.24 1.89E-06 2.27E-05
33 PIK3CG 5.16 1.46E-12 1.06E-10
34 PLXDC1 1.95 3.71E-05 3.11E-04
35 PLXND1 1.63 1.40E-03 6.98E-03
36 PTEN 1.57 7.89E-04 4.29E-03
37 ROBO1 3.82 1.68E-16 4.23E-14
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PDAC subgroups. From > 9800 mutated genes, only 
KBTBD6 which has no known role in angiogenesis, was 
differentially mutated when comparing the strong and 
weak subgroups (P < 0.05; Supplementary Table 2). 
No other genes were differentially mutated, and the 
mean number of mutated genes in each PDAC patient 
was similar. Thus, specific gene mutations and overall 
mutational burden do not necessarily explain the different 
angiogenic signatures in PDAC. 
PdAc vessel density correlates with the presence 
of sMAd4
We next sought to determine whether specific 
pathway alterations could explain the different angiogenic 
gene signatures present in PDAC. Accordingly, we 
subjected the 79 differentially expressed angiogenesis 
genes to Ingenuity Pathway Analysis (IPA). IPA identified 
TGF-β as a significant upstream regulator of their 
expression (P = 1.17 × 10−11) suggesting that PDACs with 
a strong angiogenic signature could also exhibit a TGF-β 
gene signature. To explore this possibility, we performed 
hierarchical clustering which preserved the order of 
patient samples that clustered together in the angiogenesis 
analysis, but was focused on a dataset of 186 TGF-β target 
genes from the gene set enrichment analysis (GSEA) 
Molecular Signatures Database (MSigDB). In the strong 
PDAC subgroup, a subset of TGF-β target genes were 
up-regulated and were distinct from targets up-regulated 
in PDACs with moderate or weak angiogenesis signatures 
(Figure 2A). Overall, 50 TGF-β target genes were 
increased when comparing the strong and weak PDAC 
subgroups, including pro-angiogenic CTGF and ITGA5 
(Supplementary Table 3). Moreover, ITGB1, NRP1 and 
FLT4 (Supplementary Table 1), were increased in PDACs 
with a strong angiogenic signature, and all of these are 
38 ROCK1 1.67 1.49E-03 7.35E-03
39 ROCK2 1.74 3.24E-04 2.02E-03
40 SIRT1 1.67 1.56E-03 7.65E-03
41 STAB1 2.29 2.32E-08 4.76E-07
42 TEK 3.74 1.13E-14 1.57E-12
43 TGFBR1 1.53 9.04E-03 3.28E-02
44 TGFBR2 1.86 4.36E-05 3.56E-04
45 THBS4 5.55 7.95E-11 3.27E-09
46 THSD7A 4.72 7.58E-11 3.14E-09
47 TIE1 2.21 1.46E-07 2.35E-06
48 WASF2 1.58 1.28E-03 6.46E-03
table 2: Genes unique to the Pnet angiogenesis gene signature
number Gene symbol Fold change P-value Fdr
up-regulated
1 ANGPTL3 17.34 6.42E-03 2.41E-02
2 BAI3 47.69 2.18E-06 2.31E-05
3 FGF9 3.84 6.96E-03 2.56E-02
4 GTF2I 2.22 9.34E-05 6.47E-04
5 HIPK2 2.66 1.52E-06 1.67E-05
6 ISL1 19.37 1.82E-06 1.97E-05
7 SCG2 65.37 7.42E-06 6.87E-05
8 SRPK2 2.14 6.70E-04 3.59E-03
9 TSPAN12 3.37 2.04E-04 1.27E-03
10 VEZF1 1.73 7.18E-03 2.63E-02
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TGF-β targets (Supplementary Table 3). Thus, PDACs 
with a strong angiogenic signature exhibit increased 
expression of many TGF-β target genes. 
Notably, TGF-β3 was significantly increased in 
the strong PDAC subgroup (fold increase: 3.4; P-value: 
1.89 × 10−12; FDR 1.31 × 10−10), whereas TGF-β1 and 
TGF-β2 were not differentially expressed. Moreover, 
SMAD4 inactivation by mutation or deletion only occurred 
in ~13% of cases in the strong subgroup, but ~37% and 
~42% of cases in the moderate and weak subgroups, 
respectively (Figure 2B, Supplementary Figure 2B). Thus, 
we analyzed protein array data from the PDAC TCGA 
dataset to investigate the relationship between SMAD4 
expression and the levels of the endothelial cell-specific 
marker, CD31 (Cluster of Differentiation 31). PDACs with 
high levels of SMAD4 expressed high levels of CD31, 
whereas low levels of SMAD4 were associated with 
low CD31 (Figure 2C). To confirm these observations, 
we assessed SMAD4 and CD31 protein expression in a 
tissue microarray (TMA) of 54 human PDAC tissues using 
CD31- and wild-type SMAD4-detecting antibodies [19]. 
Nuclear SMAD4 was present in the cancer cell nuclei of 
23 PDACs in which CD31-positive endothelial cells (ECs) 
and vessels were abundant (Figure 2D–2E). By contrast, 
wild-type SMAD4 immunoreactivity was not detectable in 
the cancer cells in 31 PDACs, and in these tissues CD31 
immunoreactivity was sparse (Figure 2D–2E). These data 
therefore suggest that the presence of wild-type SMAD4 
in pancreatic cancer cells correlates with endothelial cell 
abundance.
PdAc vessel density also correlates with the 
presence of HdAc9
We next assessed patient survival to determine 
whether the strong angiogenesis gene signature could be 
useful for PDAC prognosis. The majority of PDAC cases 
in the TCGA dataset are Stage IIB (73%). Therefore, 
we extracted survival information for these patients to 
compare overall survival between patients whose tumors 
are similar with respect to staging, but different with 
respect to their angiogenesis signatures. Kaplan-Meier 
analysis revealed that the median survival of patients 
in the strong angiogenesis subgroup was 592 days, and 
in the weak subgroup it was 393 days (Figure 3A). By 
contrast, there were no observed PNET deaths, with a 
median follow-up of 1410 days, and a log rank analysis 
comparing all three groups confirmed that PNET survival 
was significantly longer than the survival of PDAC 
patients (P < 0.01; Figure 3A). However, there were no 
statistically significant differences in survival between 
the PDAC subgroups (P = 0.17; Figure 3A). Thus, an 
angiogenesis signature is not necessarily prognostic in 
PDAC, but there is a tendency for patients with a strong 
angiogenesis signature to survive longer than patients who 
lack this signature. 
Given these observations, we next sought to 
determine whether the strong angiogenesis gene signature 
could be useful for predicting vessel abundance (termed 
microvessel density: MVD) in PDAC. Accordingly, we 
analyzed resected PDAC tissues for CD31 as a marker 
of endothelial cell abundance and overall MVD, and 
angiogenic genes up-regulated in the strong subgroup. 
From the 12 PDACs analyzed, 50% exhibited moderate 
to high levels of CD31 (termed CD31Hi) whereas in the 
other 50%, CD31 was low to nearly undetectable (termed 
CD31Lo) (Figure 3B). To determine whether CD31Hi 
tumors also express high levels of angiogenic genes, we 
next compared ANGPT1, TIE1, TEK, CYP1B1, HIF1A 
and HDAC9 levels in CD31Hi tumors with their levels in 
CD31Lo tumors. We selected these genes because all six 
were present in the angiogenesis signature unique to PDAC 
(Table 1), because CYP1B1 was the most significantly and 
highly up-regulated, and because ANGPT1, its receptors 
TIE1 and TEK, and HIF1A are commonly associated 
with pathways that enhance tumor angiogenesis [20, 21]. 
HDAC9 is also pro-angiogenic [22], and we recently 
reported that it is required for murine pancreatic cancer 
cells derived from the KRC (oncogenic Kras combined 
with loss of RB) genetically engineered mouse model 
to stimulate proliferation of SV40-transformed murine 
endothelial cells (SVEC4-10; [13]). Whereas ANGPT1, 
TIE1, TEK, CYP1B1 and HIF1A mRNA levels were similar 
when comparing CD31Hi with CD31Lo PDACs, HDAC9 
levels were markedly up-regulated in CD31Hi tumors 
(Figure 3C). Moreover, 34/54 (~63%) PDACs in the TMA 
exhibited strong HDAC9 immunoreactivity in the cancer 
cells, and in these tumors, CD31-positive endothelial cells 
were abundant (Figure 3D–3E). By contrast, CD31-positive 
endothelial cells were rarely detected in PDACs without 
HDAC9 immunoreactivity (20/54) (Figure 3D–3E). 
Therefore, HDAC9 is a member of the angiogenesis gene 
signature that correlates with endothelial cell abundance 
and microvessel density in PDAC.
PdAcs with an angiogenesis gene signature are 
enriched in inflammation-related genes
STAT3 is an oncogene and survival factor 
that can exert pro-angiogenic effects downstream of 
multiple inflammatory factors [23, 24]. We recently 
reported that active STAT3 is often present in cancer, 
stromal and endothelial cells in human PDAC tissues, 
and in tumors arising in the KRC mouse model [13]. 
Within murine endothelial cells, STAT3 is activated by 
pancreatic cancer cell-derived pro-inflammatory and 
pro-angiogenic factors, leading to the up-regulation of 
HDAC9 which then enhances murine endothelial cell 
proliferation [13]. It is not known, however, whether 
these pathways are associated with angiogenesis in 
human PDAC. Therefore, we conducted a GSEA 
comparing differentially expressed genes between 
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the strong and weak PDAC subgroups with gene sets 
related to inflammation. This analysis revealed that the 
transcriptome of PDACs with a strong angiogenesis 
gene signature correlated strongly with gene expression 
profiles arising from inflammatory responses (Figure 4A). 
Moreover, leading edge analysis of these GSEAs indicated 
that genes up-regulated in the strong PDAC subgroup 
were enriched in pro-inflammatory genes, including 
IL1B, IL6 and JAK2, anti-inflammatory IL10, as well 
as HDAC9. Next, hierarchical clustering was carried 
out to assess the levels of all genes annotated as either 
positive (+) or negative (−) regulators of inflammation 
in each of the PDAC subgroups. PDACs with a strong 
angiogenesis signature exhibited increased expression 
of multiple genes annotated to (+) inflammation, and a 
subset of (−) inflammation genes (Figure 4B). However, 
differential expression analysis comparing the strong 
and weak angiogenesis subgroups revealed that only 
16 (−) inflammation genes were up-regulated, whereas 
17 were down-regulated (Supplementary Table 4). By 
contrast, 28 (+) inflammation genes were up-regulated 
(Supplementary Table 5), indicating that PDACs with 
a strong angiogenesis signature are associated with 
increased expression of several transcripts that have the 
capacity to promote inflammation.
tβrI and JAK inhibition blocks angiocrine 
effects
Our findings indicate that PDACs in the strong 
angiogenesis subgroup were associated with increased 
expression of TGF-β target genes and an inflammation 
signature in which several pro-inflammatory genes, 
including Janus kinase 2 (JAK2) were increased. Moreover, 
the strong angiogenesis subgroup expressed wild-type 
SMAD4 protein that correlated with CD31 levels. Therefore, 
we next sought to determine whether inhibition of TGF-β 
type I receptor (TβRI) and/or JAK signaling pathways can 
block angiogenic effects. We used the well-known PANC-1 
human pancreatic cancer cells (PCCs), as well as our 
recently established IUSCC-PC1 cell line in 3D co-cultures 
with non-immortalized human vascular endothelial cells 
(HUVECs). Both PANC-1 cells and IUSCC-PC-1 cells 
harbor mutated KRAS (KRASG12D) and express wild-type 
Figure 2: Angiogenic gene signatures correlate with increased expression of TGF-β target genes. (A) While preserving the 
order of the 8 PNET (NET) and 135 PDAC TCGA patient samples according to the angiogenesis cluster analysis, hierarchical clustering 
of RNA-Seq expression values from 186 TGF-β responsive genes indicated that a subset of TGF-β target genes are up-regulated in the 
strong angiogenic PDAC group (red = up-regulated; green = down-regulated). (b) Overall SMAD4 loss by mutation or deletion was 
significantly higher in the moderate (M) and weak (W) angiogenic PDAC subgroups compared with the strong subgroup (S) as determined 
using TCGA. Stacked bars show the total % of patients in each subgroup with SMAD4 mutations (solid bars) or deletions (hatched bars). 
*P < 0.05. (c) Analysis of protein expression data from TCGA shows that SMAD4 and CD31 levels correlate in PDAC. (d) Quantification 
of CD31 and SMAD4 immunostaining of a human PDAC tissue microarray (TMA) shows that in SMAD4-positive tumors (open bar), 
CD31 immunoreactivity is significantly higher than in SMAD4-negative tumors (closed bar). **P < 0.01. (e) Representative images of the 
SMAD4 and CD31 immunostaining on the TMA shows that CD31-positive endothelial cells and vessels (arrowhead) are present in PDACs 
with SMAD4 immunoreactivity in the PCCs (left panels), whereas in SMAD4-negative tumors CD31 immunoreactivity is rarely present 
(right panels). Insets show magnified images of boxed areas. Scale bars 50 μm.
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SMAD4 as determined by DNA sequencing. Importantly, 
establishing new PCCs diminishes the potential for 
additional mutations and clonal selections that may arise 
from serial in vivo and in vitro passaging. Thus, IUSCC-
PC-1 cells were used to confirm findings with PANC-1 cells 
which were established in 1975 [25]. To monitor changes in 
the growth for each cell type in the co-culture studies, PCCs 
and HUVECs were labeled with green and red fluorescence, 
respectively. By comparison to 3D cultures in which PCCs 
and HUVECs were cultured separately, IUSCC-PC-1 and 
PANC-1 cell proliferation was significantly enhanced by 
co-culture with HUVECs (Figure 5A–5B). Moreover, 
HUVEC proliferation was enhanced in co-cultures with 
either PCC line (Figure 5A–5B). These mitogenic effects 
were completely blocked by the combination of the JAK 
inhibitor, ruxolitinib, and the TβRI inhibitor, SB505124, but 
not by either inhibitor alone (Figure 5A–5B). These results 
therefore suggest that human PCCs exert growth-promoting 
angiogenic effects on endothelial cells, that endothelial cells 
exert mitogenic effects on PCCs, and that these events are 
suppressible by combinatorial targeting of JAK and TGF-β 
signaling pathways.
Figure 3: HdAc9 correlates with microvessel density in PdAc tumors. (A) Kaplan-Meier survival plot of patients presenting 
with Stage IIB PDAC and whose tumors express a strong (n = 34, median: 592 days) or weak (n = 15, median: 393 days) angiogenic 
profile shows no significant difference in overall survival (P-value: 0.17) between the two groups, whereas PNET (NET) survival is 
significantly longer than both PDAC subgroups (P < 0.01). (b) Immunoblots with human PDAC tissue homogenates show that CD31 is 
present in some PDACs, but is nearly undetectable in others. ERK2 confirms equivalent lane loading. Quantification of three independent 
immunoblots confirms that 6 PDACs exhibited relatively high levels of CD31 (CD31Hi; red bars) whereas the other 6 PDACs had lower 
levels (CD31Lo; blue bars). (c) Quantitative PCR for the indicated mRNAs shows that compared with CD31Lo PDACs (blue bars), 
CD31Hi PDACs (red bars) express higher levels of HDAC9 whereas the other mRNAs were not different between these groups. *P < 0.05 
(d) Immunohistochemistry shows that PDACs with strong nuclear HDAC9 immunoreactivity in the PCCs harbor CD31-positive endothelial 
cells and vessels (left panels), whereas in PDACs in which HDAC9 is undetectable, CD31 immunoreactivity is rarely present (right panels). 
Insets show magnified images of boxed areas. Scale bars 50 μm. (e) Quantification of CD31 immunostaining shows that in HDAC9-
positive tumors (open bar), CD31 immunoreactivity is significantly higher than in HDAC9-negative tumors (closed bar). **P < 0.01.
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JAK1 mediates endothelial cell growth
Analysis of genes involved in JAK signaling 
revealed that 40 genes in this pathway were up-regulated 
in PDACs with a strong angiogenic signature, including 
JAK1, JAK2 and JAK3 (Figure 6A, Supplementary 
Table 6). Because ruxolitinib selectively targets JAK1 
and JAK2 [26], we next assessed whether one or both 
of these kinases are involved in the mitogenic cross-talk 
between human PCCs and HUVECs. Phosphorylated 
JAK1 (p-JAK1) was only detectable in co-cultures of 
PCCs and HUVECs, and its levels were suppressed by the 
combination of SB505124 and ruxolitinib (Figure 6B–6C). 
By contrast, JAK2 phosphorylation was not affected by 
co-culture, or by SB505124 and ruxolitinib (Figure 6B). 
Moreover, this combination failed to induce cleaved 
PARP in PCCs or HUVECs, or in co-cultures of these 
cells (Figure 6B). To determine whether increased p-JAK1 
occurred in HUVECs, PCCs or both cell types, we added 
conditioned media from IUSCC-PC1 or PANC-1 cells 
to HUVECs, and, conversely, conditioned media from 
HUVECs to PCCs. Conditioned media from the PCCs 
markedly enhanced p-JAK1 levels and induced SMAD 
phosphorylation in HUVECs (Figure 6D–6E). By contrast, 
conditioned media from HUVECs failed to induce JAK1 
phosphorylation in the PCCs (not shown), but stimulated 
SMAD phosphorylation (Figure 6F–6G). Thus, JAK1 
activation is endothelial cell-specific whereas canonical 
TGF-β signaling pathways are activated in both cell types. 
To assess the role of JAK1 in endothelial cell growth, and 
in mediating angiocrine effects on PCCs we used shRNAs 
to suppress JAK1 expression in HUVECs. Both shRNAs 
markedly attenuated JAK1 expression levels in HUVECs, 
and suppressed their proliferation and ability to stimulate 
PCC growth (Figure 7A–7D). Therefore, endothelial 
JAK1 is required for the angiocrine effects of endothelial 
cells on PCCs.
dIscussIon
PDACs are desmoplastic and hypoxic tumors. 
Nonetheless, PDACs exhibit foci of EC proliferation, and 
a positive correlation has been reported between blood 
Figure 4: Angiogenic PDACs have an inflammatory profile. (A) Gene Set Enrichment Analysis (GSEA) indicates that genes 
up-regulated during transplant rejection (top) or during the inflammatory response (bottom) correlate with genes up-regulated in the 
strong angiogenic PDAC subgroup when compared to the weak angiogenic PDAC subgroup (family-wise error rate (FWER) < 0.001). 
(b) While preserving the order of the 8 PNET (NET) and 135 PDAC TCGA patient samples according to the angiogenesis cluster analysis, 
hierarchical clustering of RNA-Seq expression values from 85 positive (top) or 81 negative (bottom) regulators of inflammation indicates 
that the strong angiogenic PDAC subgroup up-regulates subsets (outlined) of both positive and negative regulators of inflammation 
(red = up-regulated; green = down-regulated). Differential expression analysis reveals up-regulation of 28 positive and 16 negative 
regulators of inflammation and down-regulation of 7 positive and 17 negative regulators of inflammation, suggesting a tipping of the scale 
to a pro-inflammatory environment (|Fold Change > = 1.5|, False Discovery Rate (FDR) < 0.05).
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vessel density, tumor VEGF-A levels, and increased 
frequency of hepatic metastases and disease progression 
in PDAC [27–29]. Despite these observations, PDACs 
are refractory to VEGF-A-targeted therapies [30–32]. 
However, recent clinical trials have raised the possibility 
that targeting several pro-angiogenic signaling pathways 
may be beneficial in PDAC. For example, the VEGF 
and PDGF receptor inhibitor vatalanib was recently 
shown to slightly improve survival in metastatic PDAC 
[33], and TL-118, which combines four agents with a 
potential to inhibit angiogenesis, has also demonstrated 
promising results in early phase clinical trials [34]. Taken 
together, these observations underscore the need to have 
an improved understanding of the role of angiogenesis in 
PDAC.
In the present study, we utilized RNA-seq data 
from the recently updated pancreatic tumor TCGA 
dataset to explore relationships between angiogenesis and 
angiogenic gene expression levels. In agreement with our 
previous findings [13], this transcriptome analysis served 
to divide PDACs into three distinct subgroups based 
on their overall angiogenic gene expression profiles. 
Importantly, the recently expanded TCGA data for 
PDAC revealed that the strong angiogenesis signature is 
Figure 5: TβRI and JAK1-2 inhibition suppress human PCC and EC growth. (A) 3D co-cultures of IUSCC-PC1 or PANC-1 
human PCCs (green) and human ECs (HUVECs, red) shows that compared with vehicle (DMSO [0.05%]), ruxolitinib [100 nM] together 
with SB505124 [2 μm] suppress PCC and EC growth. Shown are representative brightfield and fluorescent images from three independent 
experiments. Scale bars, 200 μm. (b) Fluorescence intensity quantification shows that compared with 3D cultures in which IUSCC-PC1 
or PANC-1 PCCs and HUVECs are cultured independently (closed bars), culturing ECs and PCCs together in 3D (open bars) significantly 
enhances PCC and EC growth, which is completely blocked when ruxolitinib and SB505124 are combined, but not by either inhibitor 
alone. Data are mean ± SEM from three independent experiments. *P < 0.05, and **P < 0.01.
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Figure 6: Angiogenic PdAcs are enriched in JAK-stAt signaling genes. (A) Compared with the weak angiogenic PDAC 
subgroup, 40 or 8 JAK/STAT signaling pathway genes are up-regulated in the Strong or Moderate Angiogenic groups, respectively. 
(b) Immunoblots with 3D culture lysates from IUSCC-PC1 or PANC-1 human PCCs with or without HUVECs (ECs) show that endothelial 
(CD31) and epithelial (CK19) markers are present in PCC:EC co-cultures, in which p-JAK1 but not p-JAK2 levels are markedly increased. 
SB505124 [2 μm] together with ruxolitinib [100 nM] suppresses p-JAK1, but does not induce PARP cleavage. By contrast, gemcitabine 
(Gem, [10 µM]) enhances cleaved PARP levels in co-cultured cells. (c) Quantification confirms that SB505124 and ruxolitinib (open bars) 
significantly decreases p-JAK1 levels in co-cultured cells. (d–G) Immunoblots with EC (D) or PCC (F) lysates show that conditioned media 
(CM) from PCCs increases p-JAK1 and p-SMAD levels in ECs, whereas CM from ECs increases p-SMAD levels in PCCs. Quantification 
confirms that PCC CM (E, open bars) significantly increases p-JAK1 and p-SMAD in ECs, and that EC CM (G, open bars) significantly 
increases p-SMAD in PCCs. ERK2 in B, D and F confirms equivalent lane loading. Data in C, E and F are presented as mean ± SEM from 
three independent experiments. *P < 0.05, #P < 0.01.
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present in ~35% of PDACs, underscoring the prevalence 
of this gene profile in PDAC. The expanded dataset also 
afforded the opportunity to conduct a preliminary analysis 
of angiogenic gene expression in PNETs. All 8 of the 
PNET cases currently available for analysis exhibited a 
similar angiogenic profile, but some of these genes were 
distinct from those up-regulated in PDAC. For example, 
PNETs exhibited marked increases in ANGPTL3, ISL1 
and SCG2 expression. Angiopoietin-like 3 (ANGPTL3) 
stimulates endothelial cell migration and vessel formation 
[35], whereas Islet-1 (ISL1) and secretoneurin which is 
processed from SCG2, enhance endothelial growth and 
survival [36–38] and both of these genes are commonly 
associated with PNETs [39–42]. By contrast, other genes 
overlapped with PDACs, including BMPER, GPLD1, 
and NXRN1 and NXRN3. BMPER is pro-angiogenic, 
and enhances endothelial migration and tube formation 
by stimulating FGF receptor (FGFR) signaling [43, 44]. 
Although targeting FGFR signaling is effective in murine 
PDAC and PNET models [45, 46], FGFR-2 was markedly 
decreased in PNETs. FGFR-2 exists as two major splice 
isoforms with different C-terminal portions in the 
Ig-like region closest to the intracellular domain, and 
both isoforms have been implicated in PDAC biological 
aggressiveness [47, 48]. Therefore, the marked decrease 
in FGFR-2 expression in PNETs, which has not been 
previously reported, may contribute to the attenuated 
aggressiveness of PNETs by comparison with PDAC. By 
contrast, GPLD1, NXRN1 and NXRN3 were markedly 
increased in PNETs. Phospholipase D1 (encoded for 
by PLD1 genes) and neurexins (encoded for by NXRN 
genes) are also pro-angiogenic, and exert their effects by 
modulating VEGF and TIE-2 receptor signaling [49–53]. 
Given that the fold increases in expression for these 
angiogenic genes were greater in PNETs than in PDACs, 
these observations raise the possibility that they could 
contribute to the grossly angiogenic phenotype of PNETs. 
 PDACs exhibited increased expression of many 
more angiogenic genes that included a larger set of pro-
angiogenic genes distinct from those up-regulated in 
PNETs. For example, ANGPT1, COL15A1, COL4A3, 
CXCL12 (SDF-1), and ITGAV and ITGB1 were only 
up-regulated in PDACs, and together constituted part 
of a complex network of functionally connected genes. 
Figure 7: JAK1 is required for endothelial cell growth and angiocrine effects on pancreatic cancer cells. (A–b) Two 
different JAK1-targeting shRNAs decrease JAK1 expression in HUVECs (A), and significantly decrease HUVEC proliferation (B, open 
bars) compared with Sham-transduced control cells. Cell proliferation was assessed using MTT assay, and data are presented as mean ± 
SEM from three independent experiments. ERK2 in (A) confirms equivalent lane loading. (c) 3D co-cultures with IUSCC-PC1 PCCs 
(green) and HUVECs (red) transduced with a non-targeting control (EC Sham) or JAK1 shRNA (EC shJAK1) shows that JAK1 knockdown 
in ECs suppresses PCC and EC growth. Shown are representative brightfield and fluorescent images from three independent experiments. 
Scale bars, 200 μm. (d) Fluorescence intensity quantification confirms that JAK1 knockdown in ECs suppresses PCC and EC growth in 3D 
co-cultures (hatched bars). Data are mean ± SEM from three independent experiments. *P < 0.05, #P < 0.01.
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ANGPT1 enhances endothelial cell survival through 
the receptor tyrosine kinase, TIE2 [20], whereas SDF-1, 
collagens and integrins enhance endothelial cell migration 
and adhesion [54–56]. Together, these observations 
underscore the complexity of angiogenesis in PDAC, and 
the divergence between PDAC and PNET in relation to 
their angiogenic gene expression profiles. Moreover, these 
findings highlight the presence of multiple pro-angiogenic 
pathways in PDAC, which may explain why PDACs 
evade therapies that target single angiogenic pathways 
[30, 32] while PNETs respond to bevacizumab and to the 
angio-kinase inhibitors sunitinib and sorafenib [57–59]. 
The TGF-β type I (TβRI) and type II receptors 
(TβRII) were also up-regulated in PDACs but not in 
PNETs, and investigation into pathways through which the 
strong angiogenic PDAC signature could arise revealed 
that patients who have this signature also have signatures 
rich in TGF-β targets and inflammation-related genes. All 
three TGF-β isoforms are overexpressed in PDAC and 
are associated with poor outcome [60], and within the 
tumor microenvironment TGF-βs modulate angiogenesis, 
but enhance or suppress it depending on which genes are 
regulated and how they influence the angiogenic switch 
[9, 61]. For example, restoration of canonical TGF-β 
signaling in SMAD4-deficient pancreatic cancer cells 
(PCCs) has been reported to suppress angiogenesis by up-
regulating anti-angiogenic thrombospondin-1 (THBS1) 
[62], and we detected a 5.63-fold increase in THBS1 in 
patients with a strong angiogenic signature. However, 
SMAD4 re-expression in BxPC3 PCCs fails to suppress 
angiogenesis in vivo [63], and blocking TGF-β signaling 
suppresses tumor growth, metastasis, and angiogenesis 
in orthotopic mouse models [13, 64, 65]. Moreover, 
disrupting canonical TGF-β signaling by SMAD4 deletion 
suppresses metastasis in a genetically engineered mouse 
model (GEMM) of PDAC [66]. We recently reported that 
canonical TGF-β pathways stimulate pro-angiogenic gene 
expression in murine PCCs [13], and in the present study 
we determined that SMAD4 correlates with endothelial 
cell abundance in human PDAC tissues, suggesting that 
active canonical TGF-β signaling pathways promote 
angiogenesis in PDAC.
Inflammatory cells from different lineages enhance 
tumor angiogenesis by secreting pro-inflammatory and 
pro-angiogenic cytokines into the tumor milieu [9, 67]. 
Here, we identified inflammatory genes that were only 
elevated within the strong angiogenic PDAC subgroup 
that included multiple members of JAK-STAT signaling 
pathways, and both positive and negative regulators 
of inflammation. Overall, 16 negative regulators of 
inflammation were increased, and several of these are 
pro-angiogenic. For example, ADIPOQ which rescues 
impaired angiogenesis in ADIPOQ-null mice [68, 69] and 
stimulates endothelial migration and tube formation [70] 
was increased by ~11-fold, whereas pro-angiogenic GHSR 
and NLRP3 [71–74] were increased by ~4.8- and ~4-fold, 
respectively. Moreover, up-regulated positive regulators of 
inflammation included TLR2 and TLR7, both of which are 
pro-angiogenic [75], and IL6, the IL-6 receptor (IL6ST) 
and all three Janus kinases (JAK1-3). TLR7 activates 
STAT3 and markedly accelerates pancreatic tumorigenesis 
in GEMMs [76], whereas the IL-6 receptor (IL6ST) forms 
a signaling cascade with JAKs which activates STAT3 to 
enhance endothelial growth [77]. STAT3 is an important 
pro-survival factor in PDAC [78] and enables PCCs from 
the KRC GEMM to stimulate murine EC growth by 
up-regulating HDAC9 [13]. HDAC9 is a class IIa histone 
deacetylase that mediates pro-inflammatory cytokine 
release from macrophages [79, 80], polarizes naïve T-cells 
into regulatory T-cells [81, 82], and exerts angiogenic 
effects in endothelial cells [13, 22]. In the present study, 
we determined that HDAC9 is strongly expressed in the 
cancer cells in PDAC tissues with abundant vasculature, 
raising the possibility that HDAC9 could be a new marker 
for angiogenesis in PDAC.
In summary, our study highlights marked congruity 
between pro-inflammatory genes, TGF-β target genes, 
and the presence of a strong angiogenic signature. 
Thus, targeting inflammatory and/or TGF-β pathways in 
PDAC patients could serve to disrupt tumor-promoting 
angiogenic effects. In support of this conclusion, targeting 
these pathways together using SB505124 and ruxolitinib 
suppressed endothelial JAK1 activation in 3D co-cultures 
of human pancreatic cancer cells (PCCs) and human 
endothelial cells (ECs), and prevented ECs from exerting 
proliferative angiocrine effects on PCCs. This observation 
is consistent with our previous findings using a murine 
model system, but demonstrates that such a mechanism 
also exists in human ECs and PCCs, and that these 
effects are mediated in part, by endothelial JAK1. Taken 
together, the findings in the current study suggest that 
targeting TGF-β together with JAK1 pathways could be 
an advantageous approach to suppress cancer cell growth 
and angiogenesis in PDAC, and raise the possibility that 
this combination may be especially effective in patients 
whose tumors have wild-type SMAD4, exhibit HDAC9-
positivity, or express an angiogenic gene signature.
MAterIAls And MetHods
Hierarchical clustering, differential expression 
and gene set enrichment analysis
Normalized RNA-Seq RSEM [83] reads and 
raw count reads were downloaded from the TCGA 
pancreatic ductal adenocarcinoma dataset (PAAD) on 
December 31, 2014 from http://cancergenome.nih.gov/. 
This transcriptome dataset includes 183 patient samples. 
179 of these are tumor samples (2 from one patient), 
and 4 are matched normal. Thus, there are 178 different 
tumor samples. Of these, 135 are confirmed PDAC and 
8 are PNET. Other tumors (14/178) have additional 
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histopathological characteristics, whereas 21/178 are 
mucinous colloid carcinomas, undifferentiated carcinomas 
or an unknown histological type. Hierarchical clustering 
was performed in R using data from PNETs (n = 8) or 
confirmed PDACs without additional histopathological 
characteristics (n = 135). Normalized RSEM values of 
129 angiogenesis genes [13] were centered and scaled, 
and rows were clustered using a Pearson correlation 
distance and average linkage function, and columns were 
clustered using a Euclidean distance and complete linkage 
function. The centered and scaled expression values were 
graphed as a heatmap (red = up-regulated; green = down-
regulated) in combination with the associated row and 
column dendrograms using the heatmap.2 function of the 
gplots R package.
For TGF-β, 192 HUGO gene names annotated to 
the “TGFB_UP.V1_UP” gene set were obtained from 
the gene set enrichment analysis (GSEA) Molecular 
Signatures Database. 190 of these had associated HGNC 
IDs, which were mapped to 190 Entrez gene IDs using 
the Homo sapiens gene file from NCBI. Four genes were 
excluded because 2 were already part of the angiogenic 
signature and 2 did not have TCGA RNA-Seq information. 
Clustering of 186 genes was performed as described 
above, but columns were not clustered. Instead, they 
were arranged in the same order as in the angiogenesis 
profile. Differential expression analyses were performed 
using DESeq [84] on the raw count data. Statistical criteria 
for differential gene expression were (|Fold Change (FC)| 
≥ 1.5; FDR < 0.05). 
For inflammation, GSEAs were performed using the 
Hallmark Gene Sets collection in the GSEA Molecular 
Signatures Database and the GSEAPreranked tool (v.2.2.0) 
on a ranked list of genes that were sorted according to fold 
change differences between the strong and weak PDAC 
subgroups [85, 86]. Clustering and differential expression 
was performed as described above using UniProt 
IDs annotated to positive regulation of inflammation 
(GO:0050729) or negative regulation of inflammation 
(GO:0050728) and the BioMart Bioconductor package to 
convert ids to Entrez gene ids [87–90].
To assess angiogenesis gene interactions, we 
used GeneMANIA [91]. Briefly, the angiogenesis genes 
unique to PNET (10) or PDAC (48), or genes that were 
common to both (31) were analyzed using GeneMANIA’s 
pathway datasets.  Any genes that were not directly 
connected were removed from the resulting network. 
For JAK-STAT analysis, 145 genes in the KEGG_JAK_
STAT_SIGNALING_PATHWAY pathway were obtained 
from GSEA. Fold changes and FDRs for these genes 
were isolated from the DESeq analysis, and differential 
expression was defined as (|Fold Change| > = 1.5; FDR 
< 0.05), and fold changes were graphed in a heatmap using 
the heatmap.2 function of the gplots R package. Red or 
green represent up- or down-regulation, respectively. Gray 
represents genes not differentially expressed.
Mutation, deletion and protein expression 
analysis
The curated mutation maf file (v.1.2.0) was 
downloaded on December 31, 2014 and included 
information from 98 PDAC cases and 3 PNET cases. 
Silent mutations were removed. Then, a matrix of genes 
and samples was built with each gene being coded as 
1 (non-silently mutated), 0 (silently mutated or not 
mutated) or NA (no data available). Therefore, multiple 
non-silent mutations in a gene would only be counted once 
per gene. R was used to plot the mutation profiles of the 
samples in the same order as they appear in the cluster 
analysis. Significant differences in mutational frequencies 
were determined using a Fisher’s exact test. P < 0.05 was 
considered statistically significant. 
PDAC TCGA copy number data (level 4) was 
downloaded from the April 2, 2015 Broad GDAC Firehose 
GISTIC analysis run [92, 93]. The all_thresholded.by_
genes.txt file was used, which classifies genes as having 
a copy number of −2 (deep loss, possibly a homozygous 
deletion), −1 (shallow loss, possibly a heterozygous 
deletion), 0 (diploid), 1 (low-level amplification), or 
2 (high-level amplification). Of the PNET and PDAC 
samples, all 8 PNETs and 134 PDACs had copy number 
data. R was used to plot copy number profiles in the same 
order in the cluster analyses. For combining SMAD4 
mutation and deletion frequency, we used 97 PDAC 
samples that had both mutation and copy number data, 
with 40, 38, and 19 samples belonging to the Strong, 
Moderate, and Weak Angiogenic groups, respectively. 
Frequencies of samples with a mutation or deep deletion 
in SMAD4 were compared among the groups using a 
Fisher’s exact test, with P < 0.05 considered significant.
Normalized reverse phase protein array (RPPA) 
values were downloaded from the TCGA PDAC dataset. 
Of the 135 PDAC used in the hierarchical clustering, 
85 PDAC samples had protein expression information. 
CD31 and SMAD4 protein expression values for the 85 
PDAC samples were used for graphing and correlation 
calculation.
survival analysis
Survival information for PDAC and PNET patients 
was downloaded on December 31, 2014 from http://
cancergenome.nih.gov/. All patients had associated 
clinical information on days to death or days to last 
follow-up (censored). Overall survival was plotted using 
a Kaplan-Meier curve.
cell lines and 3-dimensional (3d) culture
PANC-1 (CRL-1469) pancreatic cancer cells 
(PCCs) were from ATCC. The IUSCC-PC-1 cell line was 
established from a patient-derived orthotopic xenograft 
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in an athymic mouse [13]. IUSCC-PC-1 cells were 
authenticated, and confirmed to be human and free of 
pathogens and other cell types by IDEXX Bioresearch 
(St. Louis, MO). By sequencing, the cell line harbored a 
KRAS mutation (KRASG12D) but lacked SMAD4 mutations, 
and readily formed tumors in nude mice. HUVEC 
(CRL-1730) endothelial cells (ECs) were from ATCC. PCCs 
were cultured in DMEM with 1% antibiotic (100 units/ml 
penicillin; 100 mg/ml streptomycin) and 5% FBS. HUVECs 
were cultured in EGM-2 medium (Lonza, Walkersville, MD). 
HUVECs were transduced with lentivirus containing JAK1-
targeting shRNAs or a non-targeting control shRNA from 
Thermo Fisher (Waltham, MA) as described [94]. PCCs and 
HUVECs were fluorescently-labeled before culturing in 3D 
as described [13].
Immunohistochemistry
The paraffin-embedded human PDAC tissue 
microarray (TMA) was obtained from the Tissue 
Procurement and Distribution core at the Indiana 
University Simon Cancer Center, and 4 µm sections 
were prepared. Immunohistochemistry was performed 
as described [65] using SMAD4 (Leica Biosystems, 
Buffalo Grove, IL), HDAC9 (Origene, Rockville, 
MD) or CD31 (BD Biosciences, Franklin Lakes, NJ) 
antibodies. Quantification was performed as described 
[13] using Aperio Imagescope software. Approval for 
the acquisition of all human tissues was granted by the 
Institutional Review Board (IRB) at the Office of Research 
Administration at Indiana University.
Immunoblotting and quantitative Pcr
Immunoblotting was performed as described [65] 
using CD31 (BD Biosciences), phosphorylated and total 
SMAD, p-JAK2, PARP (Cell Signaling Technology, 
Danvers, MA), and p-JAK1, JAK1, JAK2 and ERK2 
(Santa Cruz Biotechnology, Dallas, TX) antibodies. 
Briefly, lysates were prepared as described [65], and 
lysates from flash-frozen human PDAC tissues, and we 
prepared lysates from three different regions of each 
tumor. The three sets of lysates were immunoblotted 
separately. Quantification of band area in each immunoblot 
was performed using ImageJ software (http://imagej.nih.
gov/ij/) from three independent experiments, and mean ± 
SEM. Quantitative PCR (qPCR) was performed for the 
indicated mRNAs as described [95] using RNA extracted 
from the same flash-frozen PDAC tissues. RPS6 served as 
the endogenous control.
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